Latest Ariad Pharmaceuticals (ARIA) Headlines $ARIA
The Next Big Biotech Mover: Ariad Pharma
at The Street - Wed Mar 19, 1:00PM CDT
Ariad Pharmaceuticals could be the next biotech stock setting up for a monster move higher, according to Roberto Pedone.
What's Next for Geron and Imetelstat?
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 19, 11:05AM CDT
It's been a volatile year for clinical-stage cancer-focused biopharmaceutical company Geron , whose shares moved lower by 60% last week following the announcement of a full clinical hold of its only clinical compound, imetelstat, and rocketed...
Financial Results, Clinical Study Updates, Clinical Trial Results, Business Spin-Offs, and New Joint Ventures - Analyst Notes on ARIAD, NewLink, Puma Biotechnology, Theravance, and Ohr Pharmaceutical
PR Newswire - Wed Mar 12, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), NewLink Genetics Corporation (NASDAQ: NLNK), Puma Biotechnology, Inc. (NYSE: PBYI), Theravance, Inc. (NASDAQ: THRX), and Ohr Pharmaceutical, Inc. (NASDAQ: OHRP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Most Active Equities Technical Snapshot: SandRidge Energy, Ariad Pharma, Groupon, and Vodafone
PR Newswire - Tue Mar 11, 9:12AM CDT
The trading session on Monday, March 10, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,418.68, down 0.21% and the NASDAQ Composite closed at 4,334.45, down 0.04%. The S&P 500 finished the session 0.05% lower at 1,877.17. The losses were broad based with six of ten sectors edging lower. During the session gains in the Health Care, Energy and Consumer Staple sectors positively impacted the broader market, while some retraction came in from Industrials, Consumer Discretionary and Telecommunication Services sectors. Investor-Edge.com looks at some of the equities which were most active during the session. These include SandRidge Energy Inc. (NYSE:SD), ARIAD Pharmaceuticals Inc. (NASDAQ:ARIA), Groupon Inc. (NASDAQ:GRPN), and Vodafone Group PLC (NASDAQ:VOD). Free research on these four companies can be accessed at:
Biotech Stock Roundup: InterMune Grabs Headlines with Impressive Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 05, 9:58AM CST
Last week saw companies like Medivation, Arena and VIVUS reporting fourth quarter results. But, the spotlight remained on InterMune with its late-stage data on Esbriet.
New Appointments, Contract Extensions, Share Price Movements, Conference Schedules, and Closing of Public Offerings - Analyst Notes on Ariad, Novavax, Fonar, bluebird, and Cara
PR Newswire - Wed Mar 05, 6:24AM CST
Today, Analysts Review released its analysts' notes regarding Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Novavax, Inc. (NASDAQ: NVAX), Fonar Corp. (NASDAQ: FONR), bluebird bio, Inc. (NASDAQ: BLUE), and Cara Therapeutics Inc. (NASDAQ: CARA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Activist Investors Agitating Biotechs Bring Multi-Bagger Returns
David Williamson, The Motley Fool - Motley Fool - Fri Feb 28, 6:05PM CST
Activist investors have garnered increasing attention, as they try to bend health-care company management to focus on maximizing shareholder value.These proxy fights are important for investors, especially in biotech, where buyouts are the preferred...
Most active Nasdaq-traded stocks
AP - Thu Feb 27, 5:04PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Should You Worry About the Short Interest in Ariad Pharmaceuticals (ARIA)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 9:04AM CST
Should You Worry About the Short Interest in Ariad Pharmaceuticals (ARIA)?
ARIAD Pharmaceuticals, Inc. Battling Back
Brian Orelli, The Motley Fool - Motley Fool - Wed Feb 26, 5:30PM CST
After getting its drug pulled off the market for a few months, the relaunch of ARIAD Pharmaceuticals ' Iclusig is going about as good as could be expected. When Iclusig was pulled off the market, there were 640 leukemia patients on the drug....
Roundtable Top Picks for the Week of Feb. 24th - Video Blog
Panel Of Zacks Experts - Zacks Investment Research - Wed Feb 26, 3:31PM CST
Ideas for ETFs, Pharmaceuticals and REITS. Opportunities covered include Market Vectors Wide Moat ETF (MOAT), Ariad Pharmaceuticals (ARIA) and Excel Trust (EXL).
ARIAD's Q4 Loss Narrower-Than-Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 1:30PM CST
ARIAD's loss in the fourth quarter of 2013 is narrower than expected
Ariad Pharmaceuticals' Q4 Loss Widens 23% on Higher Expenses
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 25, 11:07AM CST
Ariad Pharmaceuticals , the highly controversial and volatile biopharmaceutical company that had its lead drug, Iclusig, pulled from pharmacy shelves for a few weeks by the Food and Drug Administration and then reinstated with more encompassing...
ARIAD Reports 2013 Financial Results and Outlines Key Objectives for 2014
Business Wire - Tue Feb 25, 6:36AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments.
ARIAD to Present at the Cowen and Company 34th Annual Health Care Conference
Business Wire - Mon Feb 24, 6:35AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Cowen and Company 34th Annual Health Care Conference being held in Boston. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company's business on Tuesday, March 4, at 10:40 a.m. (ET).
The Fool Looks Ahead
Rick Munarriz, The Motley Fool - Motley Fool - Sat Feb 22, 7:45AM CST
There's never a dull week on Wall Street. Let's go over some of the news that will shape the week to come. Monday The market kicks off the new trading week with SolarCity reporting. The Elon Musk-fronted installer of solar energy solutions...
ARIAD Expands Its Board of Directors with Appointment of Alexander J. Denner, Ph.D. of Sarissa Capital Management
Business Wire - Fri Feb 21, 6:35AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the appointment of Alexander J. Denner, Ph.D. to a two-year term on the Company's Board of Directors, effective immediately. With the addition of Dr. Denner, who serves as the chief investment officer and founding partner of Sarissa Capital Management LP, the Board now comprises nine directors, eight of whom are independent. The Company will also appoint another independent director to the Board, who will be selected by the Board and be subject to Dr. Denner's concurrence.
3 Stocks to Get on Your Watchlist
Sean Williams, The Motley Fool - Motley Fool - Wed Feb 19, 4:35PM CST
I follow quite a lot of companies, so the usefulness of a watchlist for me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time...
The Next Big Biotech Mover: Ariad Pharma
at The Street - Wed Mar 19, 1:00PM CDT
Ariad Pharmaceuticals could be the next biotech stock setting up for a monster move higher, according to Roberto Pedone.
What's Next for Geron and Imetelstat?
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 19, 11:05AM CDT
It's been a volatile year for clinical-stage cancer-focused biopharmaceutical company Geron , whose shares moved lower by 60% last week following the announcement of a full clinical hold of its only clinical compound, imetelstat, and rocketed...
Financial Results, Clinical Study Updates, Clinical Trial Results, Business Spin-Offs, and New Joint Ventures - Analyst Notes on ARIAD, NewLink, Puma Biotechnology, Theravance, and Ohr Pharmaceutical
PR Newswire - Wed Mar 12, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), NewLink Genetics Corporation (NASDAQ: NLNK), Puma Biotechnology, Inc. (NYSE: PBYI), Theravance, Inc. (NASDAQ: THRX), and Ohr Pharmaceutical, Inc. (NASDAQ: OHRP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Most Active Equities Technical Snapshot: SandRidge Energy, Ariad Pharma, Groupon, and Vodafone
PR Newswire - Tue Mar 11, 9:12AM CDT
The trading session on Monday, March 10, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,418.68, down 0.21% and the NASDAQ Composite closed at 4,334.45, down 0.04%. The S&P 500 finished the session 0.05% lower at 1,877.17. The losses were broad based with six of ten sectors edging lower. During the session gains in the Health Care, Energy and Consumer Staple sectors positively impacted the broader market, while some retraction came in from Industrials, Consumer Discretionary and Telecommunication Services sectors. Investor-Edge.com looks at some of the equities which were most active during the session. These include SandRidge Energy Inc. (NYSE:SD), ARIAD Pharmaceuticals Inc. (NASDAQ:ARIA), Groupon Inc. (NASDAQ:GRPN), and Vodafone Group PLC (NASDAQ:VOD). Free research on these four companies can be accessed at:
Biotech Stock Roundup: InterMune Grabs Headlines with Impressive Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 05, 9:58AM CST
Last week saw companies like Medivation, Arena and VIVUS reporting fourth quarter results. But, the spotlight remained on InterMune with its late-stage data on Esbriet.
New Appointments, Contract Extensions, Share Price Movements, Conference Schedules, and Closing of Public Offerings - Analyst Notes on Ariad, Novavax, Fonar, bluebird, and Cara
PR Newswire - Wed Mar 05, 6:24AM CST
Today, Analysts Review released its analysts' notes regarding Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Novavax, Inc. (NASDAQ: NVAX), Fonar Corp. (NASDAQ: FONR), bluebird bio, Inc. (NASDAQ: BLUE), and Cara Therapeutics Inc. (NASDAQ: CARA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Activist Investors Agitating Biotechs Bring Multi-Bagger Returns
David Williamson, The Motley Fool - Motley Fool - Fri Feb 28, 6:05PM CST
Activist investors have garnered increasing attention, as they try to bend health-care company management to focus on maximizing shareholder value.These proxy fights are important for investors, especially in biotech, where buyouts are the preferred...
Most active Nasdaq-traded stocks
AP - Thu Feb 27, 5:04PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Should You Worry About the Short Interest in Ariad Pharmaceuticals (ARIA)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 9:04AM CST
Should You Worry About the Short Interest in Ariad Pharmaceuticals (ARIA)?
ARIAD Pharmaceuticals, Inc. Battling Back
Brian Orelli, The Motley Fool - Motley Fool - Wed Feb 26, 5:30PM CST
After getting its drug pulled off the market for a few months, the relaunch of ARIAD Pharmaceuticals ' Iclusig is going about as good as could be expected. When Iclusig was pulled off the market, there were 640 leukemia patients on the drug....
Roundtable Top Picks for the Week of Feb. 24th - Video Blog
Panel Of Zacks Experts - Zacks Investment Research - Wed Feb 26, 3:31PM CST
Ideas for ETFs, Pharmaceuticals and REITS. Opportunities covered include Market Vectors Wide Moat ETF (MOAT), Ariad Pharmaceuticals (ARIA) and Excel Trust (EXL).
ARIAD's Q4 Loss Narrower-Than-Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 1:30PM CST
ARIAD's loss in the fourth quarter of 2013 is narrower than expected
Ariad Pharmaceuticals' Q4 Loss Widens 23% on Higher Expenses
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 25, 11:07AM CST
Ariad Pharmaceuticals , the highly controversial and volatile biopharmaceutical company that had its lead drug, Iclusig, pulled from pharmacy shelves for a few weeks by the Food and Drug Administration and then reinstated with more encompassing...
ARIAD Reports 2013 Financial Results and Outlines Key Objectives for 2014
Business Wire - Tue Feb 25, 6:36AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments.
ARIAD to Present at the Cowen and Company 34th Annual Health Care Conference
Business Wire - Mon Feb 24, 6:35AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Cowen and Company 34th Annual Health Care Conference being held in Boston. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company's business on Tuesday, March 4, at 10:40 a.m. (ET).
The Fool Looks Ahead
Rick Munarriz, The Motley Fool - Motley Fool - Sat Feb 22, 7:45AM CST
There's never a dull week on Wall Street. Let's go over some of the news that will shape the week to come. Monday The market kicks off the new trading week with SolarCity reporting. The Elon Musk-fronted installer of solar energy solutions...
ARIAD Expands Its Board of Directors with Appointment of Alexander J. Denner, Ph.D. of Sarissa Capital Management
Business Wire - Fri Feb 21, 6:35AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the appointment of Alexander J. Denner, Ph.D. to a two-year term on the Company's Board of Directors, effective immediately. With the addition of Dr. Denner, who serves as the chief investment officer and founding partner of Sarissa Capital Management LP, the Board now comprises nine directors, eight of whom are independent. The Company will also appoint another independent director to the Board, who will be selected by the Board and be subject to Dr. Denner's concurrence.
3 Stocks to Get on Your Watchlist
Sean Williams, The Motley Fool - Motley Fool - Wed Feb 19, 4:35PM CST
I follow quite a lot of companies, so the usefulness of a watchlist for me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time...
